18 ANA – ENA Profile – IgG at Test Zone Diagnostic Center

18 ANA – ENA Profile – IgG at Test Zone Diagnostic Center

The 18 ANA – ENA Profile – IgG is an advanced, highly specialized laboratory investigation designed to detect and differentiate eighteen specific antinuclear antibodies (ANA) and extractable nuclear antigens (ENA) of the IgG class in human serum. This comprehensive diagnostic panel is a critical tool in clinical immunology and rheumatology, primarily utilized for the evaluation, diagnosis, and differentiation of systemic autoimmune rheumatic diseases (SARD), also known as connective tissue diseases (CTD). At Test Zone Diagnostic Center in Lahore, Pakistan, this assay is performed using state-of-the-art multiplex line immunoassay (LIA) or enzyme-linked immunosorbent assay (ELISA) technologies, ensuring the highest level of clinical accuracy and analytical sensitivity. The human immune system normally produces antibodies to defend against foreign pathogens; however, in autoimmune disorders, it mistakenly produces autoantibodies that target the body’s own cellular components, specifically proteins within the cell nucleus and cytoplasm. The 18 ANA – ENA Profile – IgG evaluates a broad spectrum of these autoantibodies, providing a detailed molecular fingerprint of the patient’s autoimmune status.

The clinical importance of this profile cannot be overstated. While a standard ANA screening test (such as immunofluorescence assay or IFA) can indicate the general presence of antinuclear antibodies, it cannot identify the specific target antigens. The 18-antigen profile resolves this limitation by pinpointing the exact autoantibodies present, which is essential because different autoantibodies are highly specific to distinct clinical conditions. This diagnostic value allows healthcare providers to differentiate between overlapping systemic diseases, assess the risk of specific organ involvement (such as lupus nephritis or interstitial lung disease), estimate prognosis, and monitor disease activity over time. The primary benefit of this comprehensive panel is its efficiency; by testing eighteen critical markers simultaneously from a single blood draw, it eliminates the need for expensive, time-consuming sequential testing, thereby accelerating the diagnostic journey for patients experiencing complex, multi-system symptoms. Common clinical indications for ordering this profile include persistent joint pain, unexplained systemic inflammation, malar rash, photosensitivity, chronic fatigue, muscle weakness, dry eyes and mouth, Raynaud’s phenomenon, and a previously positive or borderline general ANA screening test.

Clinical Procedure: What to Expect

Patient Preparation

Preparing for the 18 ANA – ENA Profile – IgG at Test Zone Diagnostic Center is straightforward, as the test does not require strict fasting. Patients can eat, drink, and go about their daily activities normally prior to the blood draw. However, to ensure the most accurate interpretation of results, patients must follow these guidelines:

• Inform your referring physician and the laboratory staff about all current medications, especially corticosteroids, immunosuppressive drugs, or biologic therapies, as these agents can suppress immune responses and lower autoantibody levels.
• Stay well-hydrated before the procedure, as hydration makes veins more accessible and facilitates a smoother venipuncture process.
• No other special dietary restrictions or physical preparations are required.

During the Procedure

The blood sample collection for the 18 ANA – ENA Profile – IgG is a routine venipuncture procedure conducted by experienced phlebotomists at Test Zone Diagnostic Center. Upon arrival, the patient is seated comfortably in a specialized blood collection chair. The phlebotomist cleanses the skin over the selected vein, usually in the antecubital fossa of the arm, using a sterile antiseptic swab. A tourniquet is briefly applied to the upper arm to make the veins more prominent. A sterile, single-use needle is gently inserted into the vein, and the blood is collected into a serum separator tube (SST). The entire process is quick, typically taking less than five minutes, and causes only minor, temporary discomfort similar to a mild pinch. After the needle is removed, pressure is applied to the site with a sterile gauze pad to prevent bleeding, and a small adhesive bandage is applied. The collected sample is then centrifuged in the laboratory to separate the serum, which contains the IgG autoantibodies, for subsequent multiplex analysis.

When is a 18 ANA – ENA Profile – IgG Performed?

Suspected Systemic Lupus Erythematosus (SLE)

Physicians request the 18 ANA – ENA Profile – IgG when a patient presents with clinical signs suggestive of Systemic Lupus Erythematosus, such as a characteristic malar (butterfly) rash across the cheeks, photosensitivity, non-erosive arthritis affecting multiple joints, unexplained fever, and hair loss. The profile assists in the diagnosis of SLE by identifying highly specific autoantibodies, such as anti-double-stranded DNA (anti-dsDNA) and anti-Smith (anti-Sm) antibodies, which are key immunological criteria used to confirm this complex multi-system disease.

Evaluation of Sjögren’s Syndrome

When patients present with severe, chronic dryness of the eyes (keratoconjunctivitis sicca) and mouth (xerostomia), along with recurrent swelling of the salivary glands and joint pain, clinicians suspect Sjögren’s syndrome. The 18 ANA – ENA Profile – IgG is performed to detect anti-SSA (Ro) and anti-SSB (La) antibodies. Identifying these specific autoantibodies confirms the autoimmune nature of the symptoms, helping to differentiate primary Sjögren’s syndrome from secondary forms associated with other connective tissue disorders.

Diagnosis of Mixed Connective Tissue Disease (MCTD)

Mixed Connective Tissue Disease is a rare autoimmune disorder characterized by overlapping clinical features of SLE, systemic sclerosis, and polymyositis. Physicians order the 18 ANA – ENA Profile – IgG to look specifically for high titers of anti-U1-ribonucleoprotein (anti-U1-RNP) antibodies. The presence of these antibodies in the absence of other SARD-specific markers is the defining serological hallmark required to establish a definitive diagnosis of MCTD.

Investigation of Systemic Sclerosis (Scleroderma)

In patients presenting with skin thickening (sclerodactyly), severe Raynaud’s phenomenon (color changes in fingers and toes in response to cold), or esophageal motility issues, systemic sclerosis is a primary diagnostic consideration. The 18 ANA – ENA Profile – IgG evaluates specific markers, including anti-Scl-70 (topoisomerase I) and anti-Centromere B antibodies. These markers help confirm the diagnosis and classify the disease into diffuse or limited cutaneous systemic sclerosis, which have different clinical courses and prognostic outcomes.

Assessment of Polymyositis and Dermatomyositis

Patients presenting with progressive, symmetrical proximal muscle weakness, elevated muscle enzymes, or characteristic skin rashes (such as Gottron’s papules or a heliotrope rash) are evaluated for idiopathic inflammatory myopathies. The profile screens for myositis-specific antibodies, particularly anti-Jo-1. Detecting anti-Jo-1 assists physicians in diagnosing polymyositis or dermatomyositis and alerts them to the potential risk of interstitial lung disease, allowing for early therapeutic intervention.

What Does a 18 ANA – ENA Profile – IgG Detect?

The 18 ANA – ENA Profile – IgG at Test Zone Diagnostic Center evaluates a comprehensive panel of autoantibodies. It detects the presence and levels of IgG antibodies directed against the following specific antigens:

• Anti-dsDNA: Highly specific for Systemic Lupus Erythematosus (SLE) and strongly associated with lupus nephritis.
• Anti-Nucleosome: An important marker for SLE, often correlating with disease activity and renal involvement.
• Anti-Histone: Strongly associated with drug-induced lupus erythematosus and systemic lupus.
• Anti-Sm (Smith): A pathognomonic marker for SLE, highly specific for the disease.
• Anti-Ribosomal P-protein: Specific for SLE, frequently associated with neuropsychiatric manifestations.
• Anti-nRNP/Sm: Found in mixed connective tissue disease and systemic lupus erythematosus.
• Anti-U1-RNP: The key diagnostic marker for Mixed Connective Tissue Disease (MCTD).
• Anti-SS-A (Ro 60 kDa): Associated with Sjögren’s syndrome, SLE, and neonatal lupus.
• Anti-SS-A (Ro 52 kDa): Often found in Sjögren’s syndrome, myositis, and systemic sclerosis.
• Anti-SS-B (La): Highly associated with Sjögren’s syndrome and systemic lupus.
• Anti-Scl-70: Specific marker for diffuse cutaneous systemic sclerosis (scleroderma).
• Anti-PM-Scl: Associated with polymyositis-systemic sclerosis overlap syndrome.
• Anti-Jo-1: Classic marker for polymyositis and the anti-synthetase syndrome.
• Anti-CENP-B (Centromere B): Marker for limited cutaneous systemic sclerosis (CREST syndrome).
• Anti-PCNA (Proliferating Cell Nuclear Antigen): A rare but highly specific marker for SLE.
• Anti-AMA-M2: Associated with Primary Biliary Cholangitis (PBC), often co-occurring with autoimmune diseases.
• Anti-Mi-2: Specific marker for dermatomyositis, associated with a favorable prognosis.
• Anti-Ku: Found in overlap syndromes involving myositis, scleroderma, and SLE.
• Anti-DFS70: Often present in healthy individuals, helping rule out systemic autoimmune rheumatic diseases when positive in isolation.
• Anti-gp210: Associated with primary biliary cholangitis and severe disease progression.
• Anti-sp100: Another key marker for primary biliary cholangitis.
• Anti-Ro-52 IgG: Frequently evaluated for its association with congenital heart block in newborns of affected mothers.
• Anti-PL-7: Myositis-specific antibody associated with anti-synthetase syndrome.
• Anti-PL-12: Associated with interstitial lung disease and myositis.
• Anti-EJ: Rare myositis-specific antibody.
• Anti-OJ: Associated with severe muscle weakness and interstitial lung disease.

Turnaround Time and Report Access at Test Zone Diagnostic Center

Test Zone Diagnostic Center in Lahore, Pakistan, is committed to delivering accurate and timely diagnostic reports. Due to the highly specialized nature of the 18 ANA – ENA Profile – IgG test, which requires precise multiplex analysis and quality control verification by consultant immunologists, the turnaround time is typically within 3 to 5 working days. Once the analysis is complete and verified, patients receive an automated SMS notification on their registered mobile number. Reports can be easily accessed and downloaded online through the official Test Zone Diagnostic Center web portal or mobile application. Patients can also collect physical copies of their reports directly from the main laboratory or any of its designated collection centers across Lahore.

18 ANA – ENA Profile – IgG Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Anti-dsDNA	Negative	Positive (Strongly suggestive of SLE, lupus nephritis)
Anti-Sm	Negative	Positive (Highly specific for Systemic Lupus Erythematosus)
Anti-U1-RNP	Negative	Positive (Diagnostic for Mixed Connective Tissue Disease)
Anti-SS-A (Ro)	Negative	Positive (Sjögren’s syndrome, SLE, neonatal lupus risk)
Anti-SS-B (La)	Negative	Positive (Sjögren’s syndrome, SLE)
Anti-Scl-70	Negative	Positive (Diffuse systemic sclerosis, pulmonary fibrosis risk)
Anti-CENP-B	Negative	Positive (Limited systemic sclerosis / CREST syndrome)
Anti-Jo-1	Negative	Positive (Polymyositis, anti-synthetase syndrome)
Anti-Histone	Negative	Positive (Drug-induced lupus, SLE)
Anti-Ribosomal P	Negative	Positive (SLE, neuropsychiatric lupus)

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Test Zone Diagnostic Center for 18 ANA – ENA Profile – IgG?

• Experienced healthcare professionals and consultant pathologists supervising all immunological assays.
• Patient-focused care ensuring a comfortable and seamless blood collection experience.
• Quality diagnostic services utilizing advanced multiplex line immunoassay technology.
• Professional reporting with detailed quantitative and qualitative analysis of all 18 autoantibodies.
• Modern diagnostic approach adhering to international laboratory standards and quality controls.
• Comfortable environment at all collection centers in Lahore, Pakistan.
• Convenient locations across Lahore, making sample collection easily accessible.
• Commitment to accurate diagnosis to support rheumatologists in clinical decision-making.